


AUTHOR QUERY FORM

 ELSEVIER	Journal: YSCDB Article Number: 1270	Please e-mail or fax your responses and any corrections to: E-mail: corrections.eso@elsevier.thomsondigital.com Fax: +353 6170 9272
---	--	---

Dear Author,

Please check your proof carefully and mark all corrections at the appropriate place in the proof (e.g., by using on-screen annotation in the PDF file) or compile them in a separate list. Note: if you opt to annotate the file with software other than Adobe Reader then please also highlight the appropriate place in the PDF file. To ensure fast publication of your paper please return your corrections within 48 hours.

For correction or revision of any artwork, please consult <http://www.elsevier.com/artworkinstructions>.


Any queries or remarks that have arisen during the processing of your manuscript are listed below and highlighted by flags in the proof. Click on the '[Q](#)' link to go to the location in the proof.

Location in article	Query / Remark: click on the Q link to go Please insert your reply or correction at the corresponding line in the proof
Q1 Q2	Please confirm that given names and surnames have been identified correctly. Please provide the volume number and page range for Refs. [35,37,39,41,57,74].

Thank you for your assistance.

Contents lists available at [ScienceDirect](#)

Seminars in Cell & Developmental Biology

journal homepage: www.elsevier.com/locate/semcdb

Highlights

Zalpha-domains: At the intersection between RNA editing and innate immunity

Alekos Athanasiadis*

- The A to I RNA editing modification has a regulatory role in innate immunity. ►The RNA editing enzyme ADAR1 increases viral proliferation.
- Distinguishing feature of ADAR1 is a Z-DNA/Z-RNA binding domain, Zalpha. ►Zalpha domains characterize proteins of the interferon response involved in the recognition of foreign nucleic acids.

Seminars in Cell & Developmental Biology xx (2011) xxx–xxx



Contents lists available at [SciVerse ScienceDirect](http://www.sciencedirect.com)

Seminars in Cell & Developmental Biology

journal homepage: www.elsevier.com/locate/semcdb



Review

Zalpha-domains: At the intersection between RNA editing and innate immunity

Alekos Athanasiadis*

Instituto Gulbenkian de Ciência, Rua da Quinta Grande 6, 2780-156 Oeiras, Portugal

ARTICLE INFO

Article history:
Available online xxx

Keywords:
DNA structure
A to I RNA editing
Interferon response
ADAR1
Zalpha
Z-DNA

ABSTRACT

The involvement of A to I RNA editing in antiviral responses was first indicated by the observation of **genomic hyper-mutation** for several RNA viruses in the course of persistent infections. However, in only a few cases an antiviral **role** was ever demonstrated and surprisingly, it turns out that **ADARs** – the RNA editing enzymes – may have a prominent pro-viral role through the modulation/down-regulation of the interferon response. A key role in this regulatory function of RNA editing is played by ADAR1, an interferon inducible RNA editing enzyme. A distinguishing feature of ADAR1, when compared with other **ADARs**, is the presence of a Z-DNA binding domain, Zalpha. Since the initial discovery of the specific and high affinity binding of Zalpha to CpG repeats in a left-handed helical conformation, other **proteins**, all related to the interferon response pathway, were shown to have similar domains throughout the vertebrate lineage. What is the biological function of this domain family remains unclear but a significant body of work provides pieces of a puzzle that points to an important role of Zalpha **domains** in the recognition of foreign nucleic acids in the cytoplasm by the innate immune system. Here we will provide an overview of our knowledge on ADAR1 function in interferon response with emphasis on Zalpha domains.

© 2011 Published by Elsevier Ltd.

Contents

1. Introduction.....	00
2. Links between A to I RNA editing and immunity	00
2.1. Modification of viral nucleic acids.....	00
2.2. ADAR1 as a regulator of antiviral responses.....	00
3. The ADAR1 Zalpha domain.....	00
3.1. The ADAR1 Zalpha domain structure and its nucleic acids complexes.....	00
3.2. Interferon response related proteins with Zalpha domains.....	00
3.3. The non-conforming Zbeta.....	00
4. In search for the Zalpha domain target and its biological function.....	00
4.1. Nucleic acids bound by Zalpha <i>in vivo</i>	00
5. Concluding remarks	00
Acknowledgements.....	00
References.....	00

1. Introduction

In biology what you see is not always what you get. The discovery of RNA editing in *Xenopus* eggs in 1988 [1] and extensive research since have challenged a deeply rooted belief that the

sequence of transcribed nuclear RNA is a faithful copy of the genomic sequence. This RNA modification was found to be present in all metazoans and was termed A to I RNA editing because it consists in the hydrolytic deamination of adenosines (A) to inosine (I) within RNAs. Inosine base-pairs with cytosine instead of thymine and so for any biological process that involves recognition of the RNA sequence through base pairing, inosine is an equivalent of **guanosine**. As a consequence, A to I editing is able to recode amino acid **sequences** [2], to alter splice **sites** [3], create miRNA binding sites and change the specificity of miRNAs **themselves** [4].

Responsible enzymes for this RNA modification are adenosine deaminases called ADARs that show limited target sequence

Abbreviations: ADAR, **adenosine deaminase acting** on RNA; A to I, **adenosine to inosine**; PKR, **protein kinase** RNA dependent; DAI, DNA dependent Activator of IRFs; IFN, **interferon**; CNS, central nervous system; eIF2a, **eukaryotic initiation factor 2a**; HIV, **human immunodeficiency virus**.

* Tel.: +351 21 4464648; fax: +351 21 4407970.

E-mail address: alekos@igc.gulbenkian.pt

specificity [5]. Instead, their specificity is determined primarily by the secondary structure of the RNA substrate [6]. While ADARs modify a perfect RNA duplex in a promiscuous manner leading up to 50% of modified adenosines, the modification can be highly specific towards complex RNA structures containing bulges and internal loops [6].

The discovery that this RNA modification leads to functionally critical amino acid changes in vertebrate neurotransmitter receptors like the GluR-2, GluR-5 and -6 subunits of AMPA receptors, the Serotonin-2C (reviewed in [2,7]) and the γ -amino butyric acid (GABA) receptors [8] as well as in invertebrate chloride channel subunits [9], nicotinic acetylcholine receptor (nAChR) subunits [10] and several other proteins involved in fast synaptic transmission [11], led to the notion that the primary role of A to I RNA editing is to provide the much needed diversity in the proteome of the animal central nervous system (CNS). This notion however left unexplained the observed abundance of RNA editing activity outside of the CNS.

Indeed, in recent years transcriptome analysis has shown that ADARs, the A to I RNA editing enzymes, are responsible for extensive modification of 3'UTR and intronic sequences of thousands of human genes [12-15] targeting secondary structures often created by pairs of inverted repetitive elements. These findings indicate that any extensive and stable pre-mRNA stem-loop structure is accessible to ADARs and a potential target for RNA editing and have led to a wide rethinking regarding the primary role of this post-transcriptional modification.

Double stranded RNA in the cytoplasm is known to represent a danger signal indicating viral infection and several antiviral pathways are triggered by dsRNA including the RNA interference pathway in invertebrates [16] and the interferon response in vertebrate cells [17]. Through the introduction of mismatches in RNA duplexes, A to I RNA editing can reduce their double stranded nature and mark such duplexes with inosine. Could nuclear A to I RNA editing prevent the exposure of cellular mRNAs containing dsRNA structures to such antiviral pathways? Is RNA editing in the cytoplasm responsible for limiting the duration and/or the intensity of active antiviral responses? While evidence linking A to I RNA editing to antiviral responses dates back to its discovery, in the recent years several lines of research converge on an unexpected role for the editing machinery in the modulation of cellular responses to foreign nucleic acids.

2. Links between A to I RNA editing and immunity

The first evidence for a role of A to I RNA editing in immunity came with the discovery of modifications in several viral RNA genomes and viral transcripts. These modifications were shown to take the form either of genomic hyper-editing in the course of persistent viral infections or more specific RNA editing events in structured viral mRNAs. A second and independent line of evidence for a role of RNA editing in innate immunity comes from work implicating the interferon inducible ADAR1 editing enzyme in the regulation of the antiviral interferon response.

2.1. Modification of viral nucleic acids

Viral nucleic acids have been among the first known substrates of ADARs: the discovery of hyper-mutated RNA genomes of measles virus [18] and other members of the paramyxoviridae family was followed by similar observations for Vesicular Stomatitis Virus and mRNAs of the mouse polyoma DNA-virus reviewed in [19-21]. More recently similar hypermutation was observed in the invertebrate sigma RNA-virus [22] involving the ADAR enzyme of drosophilids. These findings were taken to suggest an antiviral role

of ADAR mediated RNA editing, mechanistically based on scrambling the information content of viral nucleic acids, not unlike the role of the APOBEC3 family of cytidine deaminases in retroviral restriction. However, in only few cases an antiviral role of ADARs has been demonstrated and even in these cases it still remains unclear if this is a direct result of hyper-editing of viral nucleic acids or the result of the influence of ADARs on elements of the innate immune system. Indeed, knockdown of ADAR1 in an ADAR2^{-/-} background in cell culture is shown to alter the cytopathic effects of polyoma virus infection [23] in a manner independent of the modification of viral RNA.

Specific editing within a well-defined sequence and structure context of viral nucleic acids was first demonstrated for Hepatitis D virus (HDV) [24]. Surprisingly, HDV was shown to make use of the cellular RNA editing machinery for its own needs: a stop codon in Hepatitis delta antigen is being changed to a tryptophan codon by RNA editing allowing the switch from the replication stage to the packaging stage, thus enabling viral proliferation. Interestingly, HIV replication is also shown to be enhanced in cells over-expressing ADAR1, and HIV transcripts of Rev and Tat coding sequences as well as the TAR RNA are shown to be edited by ADAR1. However, it remains unclear whether the increased replication is editing depended [25-27]. Specific RNA editing has also been found in transcripts of the Kaposi sarcoma associated virus (KSHV) [28,29], where again RNA editing appears to be adapted by the virus as the levels of editing correlate with the replicative state of the virus [29].

In summary, for both the hyper-editing and the more specific editing events observed in viral nucleic acids there is no clear evidence that these base modifications overall represent an antiviral action of ADARs. On the contrary, for viruses like Hepatitis D, RNA editing represents a valuable cellular contribution.

2.2. ADAR1 as a regulator of antiviral responses

In vertebrate species we find two genes encoding for active dsRNA dependent adenosine deaminases: ADAR1 and ADAR2. ADAR1 was the first to be discovered and expression of an N-terminally extended form of the protein was shown to be up-regulated during viral infection. Indeed, ADAR1 comes in two isoforms: a short, constitutively expressed and nuclear form (P110) and a longer, mainly cytoplasmic form (P150) which is transcribed from a different promoter responsive to type I and type II interferons [30] (Fig. 1A). The homozygous knockout of the ADAR1 gene in mice is embryonic lethal and its phenotypic characterization shows that its lethality is associated with extensive apoptosis in the hematopoietic tissue [31,32]. Further characterization of hematopoietic stem cells derived from an inducible ADAR1 gene knockout in mice shows a global upregulation of interferon responsive genes during embryonic development [33] pointing to a role of ADAR1 as a suppressor of interferon signaling. Selective knockout of the interferon controlled isoform P150 [34] suggests that this isoform is responsible for the observed embryonic lethality, although there is an ongoing debate on this matter.

The mechanism through which ADAR1 exerts control over innate immune responses has not been yet clarified. Clues however, have been obtained in studies showing that ADAR1 can antagonize protein kinase R (PKR) [35,36], a key protein of interferon response that mediates shutdown of cellular translation through the phosphorylation of eukaryotic initiation factor eIF2 α during infection. PKR is activated by dsRNA and ADAR1 can inhibit its activation either through the sequestration of dsRNA or by rendering such dsRNA unrecognizable by PKR through modification. Indeed, ectopic ADAR1 expression results in a general increase in protein translation through the inhibition of PKR [37,38] and possibly of other dsRNA activated effector proteins of the interferon response




Fig. 1. Domain organization of proteins with Zalpha motifs (A). ADAR1 isoforms P150 and P110 are indicated. RBD stands for dsRNA binding domain. The domain organization of PKR is shown for comparison with PKZ. Conserved interactions between Zalpha domains and Z-DNA (B). Tyr177, Asn173 and Trp195 positioned to recognize the characteristic Z-DNA phosphate backbone and a **guanosine** in Syn conformation.

such as the 2'-5'-oligoadenylate synthetase (OAS). A key question that arises is whether and to what extend cellular transcripts containing dsRNA can erroneously activate dsRNA dependent pathways and whether the observed extensive editing in such cellular RNA duplexes can have a preventive role. Experiments aiming to answer this question show that a single transcript containing a long dsRNA **hairpin activates** interferon response only at **abnormally high** expression levels [39]. However, given that there are possibly thousands of genes producing transcripts with embedded dsRNA structures, the activation of interferon response by cellular RNAs seems possible.

Another dsRNA dependent **pathway that** acts as an antiviral response in invertebrates but also present in **vertebrates**, is RNA interference (RNAi). An interaction between ADARs and the RNAi pathway was first suggested in experiments in *Caenorhabditis elegans* showing that the ADAR knockout phenotype can be rescued by the ablation of components of the RNAi **machinery** [40]. More recent work also in *C. elegans* **provides** support for a specific role of ADARs to protect an extensive population of dsRNA in cellular transcripts from RNAi [41]. RNAi of dsRNA in mammalian cellular transcripts has been recently demonstrated in oocytes [39] as well as the ability of ADARs, and in particular of cytoplasmic ADAR1 P150 to bind siRNA and limit the efficacy of the RNAi pathway [42].

Thus, in vertebrates ADAR1 is shown to antagonize both RNA interference and the interferon response. In doing so, ADAR1 may limit dsRNA dependent responses not only against cellular RNA but also against viral RNA. **Indeed, in** a survey for the effects of 380 IFN-regulated genes on viral proliferation, is shown to significantly enhance the replication rates of all tested viruses [43] supporting a pan-viral mechanism of enhancement.

An attractive model based on the available data ascribes a dual function of ADAR1: in the nucleus, it keeps under control the amount of cellular dsRNA that can reach dsRNA sensors in the cytoplasm while upon **prolonged activation** of the interferon pathway the P150 isoform migrates to the cytoplasm where it down-regulates antiviral responses by limiting the available dsRNA. This

model establishes ADAR1 **as a central node within** a feedback mechanism that limits runaway antiviral responses and their cytopathic effects.

What are the molecular details of ADAR1 action in the cytoplasm and what are its interactions with the cytoplasmic nucleic acids sensors? The answer to these questions must largely be found at the 296 aminoacids (in humans) long extension at the N-terminus of the interferon inducible P150 isoform. The unique recognizable and conserved feature of this segment of ADAR1 is a DNA/RNA binding domain of so far **unknown biological** function, the Zalpha.

3. The ADAR1 Zalpha domain

The N-terminal domain of ADAR1 was the surprising yield of an in vitro screen for Z-DNA binding domains in blood nuclear extracts [44] and from this discovery derives its **name: Zalpha**. It was shown that this 78aa domain of ADAR1 binds with high **affinity** [45] to CpG repeats and that the bound dsDNA forms a left-handed Z-DNA **helix, an alternative DNA conformation originally** described more than 30 years **ago** [46]. While in vitro formation of Z-DNA requires high salt concentrations, the Zalpha domain is shown to stabilize this conformation on CpG repeats under physiological salt concentrations. This makes Zalpha the first known specific Z-DNA binding protein domain.

3.1. The ADAR1 Zalpha domain structure and its nucleic acids complexes

The crystal structure of the ADAR1 Zalpha domain with a T(CG)₃dsDNA complex showed that it belongs to the larger family of winged-Helix-Turn-Helix domains (wHTH), a common DNA binding motif used in this case in a unique **configuration** [47]. A key role in the recognition of the Z-DNA backbone is played by a triplet of residues: Tyr177, Asn173 and Trp195 (all aminoacid references are based on human ADAR1-Zalpha numbering), which **are all** highly conserved among Zalpha domains (Fig. 1B). Tyr177 forms

a π -bond with the guanosine in the Syn conformation characteristic for Z-DNA, the only direct base contact made by the protein and which contributes to the discrimination between the B-DNA and Z-DNA conformations. Mutation of any residue in this triplet eliminates DNA binding [48]. The remaining protein/DNA contacts are with the characteristically shaped Z-DNA phosphate backbone, allowing further discrimination of the two DNA-conformers. Interestingly, two Zalpha domains interact with the DNA duplex without forming a physical dimer suggesting a cooperative mode of DNA-binding, a feature that is so far seen in all structures of Zalpha domains.

Formation of Z-DNA requires a dinucleotide repeated unit of alternating purine/pyrimidine bases suggesting that Zalpha could interact with CA/TG repeats in addition to CG. Such repeats however show lower propensity of Z-DNA formation and the co-crystal structure of Zalpha with these type of sequences had to wait until recently [49]. How can Zalpha bind CpG repeats in the context of a larger DNA segment that cannot be entirely in the left handed conformation? The answer to this question came with the crystal structure of a Zalpha domain bound to a B-Z junction formed at the boundaries of the left handed helix [50] demonstrating that such junctions are formed by the extrusion of a single base pair at the junction site. Similarly, Z-Z junctions are formed when Zalpha binds to imperfect CpG repeats with disruptions of the dinucleotide repeat [51]. These crystal structures document the molecular details on how Zalpha domains are able to bind Z-DNA forming segments within natural DNA molecules of variable sequence.

CpG repeats in dsRNA also adopt a left-handed helical conformation [52] known as Z-RNA and consequently, this raises the possibility that the *in vivo* target of Zalpha domains could be dsRNA. Indeed, CD-spectroscopy confirmed the interaction of Zalpha with RNA [53] and the crystal structure of ADAR1 Zalpha with an RNA (CG)₃ oligonucleotide revealed a Z-RNA structure [54] with significant similarities to Z-DNA, making Zalpha one of the rare if not unique domains capable to bind dsDNA and dsRNA of the same sequence.

This extensive structural analysis of the recombinant ADAR1 Zalpha domain demonstrated a consistent behavior and conserved interactions of the domain with CpG sequences in a variable nucleic acids context.

3.2. Interferon response related proteins with Zalpha domains

Sequence based identification of Zalpha domains in other proteins led to the delineation of the Zalpha domain family (SMART ID: SM00550), a subfamily of the winged-Helix-Turn-Helix domains. Interestingly, all proteins sharing this motif were found to be involved in the interferon response pathway, and particularly components of this antiviral pathway that relate to the intracellular recognition of foreign nucleic acids. Two Zalpha domains are found in DNA-dependent activator of IFN-regulatory factors (DAI), a cytoplasmic receptor for foreign nucleic acids and activator of the production of type I interferons, in Z-DNA dependent protein kinase (PKZ), a fish ortholog of the mammalian PKR, and the pox-viral inhibitor of interferon response E3L (Fig. 1A).

Intriguingly, isolated Zalpha domains from each of these proteins were not only shown to share high affinity for CpG repeats but also a highly conserved mode of interaction with Z-DNA as demonstrated by the crystal and NMR structures of both DAI Zalpha domains [55-57], of Yatapoxvirus E3L [58] and biochemical data from the Zalpha domain of PKZ [59]. Such results point to a common function of Zalpha domains and a functional interconnection of the proteins that contain them.

DAI (also known as DLM-1 and ZBP-1) was shown to act as a sensor for dsDNA in the cytoplasm activated by TpA and to a

lesser extent by CpG repeats [60]. A third DNA binding domain (D3) was shown to be primarily responsible for the recognition of TpA repeats and its two Zalpha domains expectedly play no role in its ability to bind B-form DNA, nevertheless they appear to be required for the activation of the signaling pathway through the interferon regulatory factor 3 (IRF3) [61]. The function of DAI seems to be specialized, playing roles in specific cell types and for viral infections by cytomegalovirus [62] and Herpes simplex virus [63] but not for example by intracellular bacteria as *Legionella pneumophila* [64].

PKZ is another nucleic acids sensor with two N-terminal Zalpha domains. This protein was found so far only in fish species like zebrafish, Atlantic salmon and goldfish and is an ortholog of the dsRNA dependent protein kinase PKR. PKZ shows a conserved and functional kinase domain but the dsRNA binding domains found in PKR are replaced by Zalpha domains [59]. This kinase appears to maintain the ability to phosphorylate eIF2a like PKR [65] and to block cellular translation. Unlike PKR however, its activity depends on the presence of CpG dsDNA and not poly I:C dsRNA [65]. While both DAI and PKZ appear responsive to CpG DNA the ability of CpG dsRNA to activate these proteins has not been tested, leaving open the possibility that these sensor proteins may respond to both DNA and RNA.

Given the role of Zalpha domains in antiviral responses, it should not come as a surprise that a Zalpha domain is found in E3L, a viral inhibitor of interferon response. E3L is a small two-domain protein found in all poxviruses whose C-terminal dsRNA binding domain blocks PKR activation and is required for viral proliferation. Its N-terminal Zalpha domain appears dispensable for viral replication in cell culture but crucial for pathogenicity in mice [66]. Interestingly, it is shown that replacement of the E3L Zalpha domain with that of ADAR1 or DAI fully supports viral pathogenicity, suggesting that Zalpha domains are functionally interchangeable [66]. The E3L Zalpha domain could function through competition for nucleic acids with DAI similar to the mechanism proposed for the inhibition of PKR by its C-terminal dsRNA binding domain. Indeed micro-array analysis shows that the Zalpha domain of E3L blocks a distinct part of the interferon signaling cascade [67] which overlaps with the IRF3-TANK-binding kinase 1 (TBK1) signaling pathway shown to be activated by DAI [60].

3.3. The non-conforming Zbeta

The uniform behavior of Zalpha domains has a single exception: A domain homologous to Zalpha is also present in the constitutively expressed isoform of ADAR1. It was named Zbeta reflecting its position within ADAR1. This domain in isolation did not demonstrate any affinity for CpG repeats and in mammalian ADAR1 Zbeta domains, the critical aminoacids corresponding to Zalpha Tyr177 and Asn173 are mutated. The crystal structure of Zbeta [68] confirmed that this domain shares the same architecture with the Zalpha domain but it also shows that Zbeta cannot form interactions with DNA equivalent to Zalpha. It is unfortunate that in proteins that contain more than one Zalpha domain (DAI, PKZ) the term Zbeta has been historically used to describe the second domain although the mammalian ADAR1 Zbeta appears to have unique properties not shared by any other member of the family. Indeed, unlike the ADAR1 Zbeta domain the second Zalpha domain of DAI does interact with CpG repeats as it is described in the structures of its complexes with DNA [56,57].

4. In search for the Zalpha domain target and its biological function

Despite the very extensive and successful work characterizing the nucleic acids binding properties of Zalpha domains, the *in vivo*

target(s) of these domains remain elusive. This is partly due to the dynamic and transient nature of Z-DNA formation and partly because the involvement of these domains in innate immunity suggests that their nucleic acids target may only be present during specific host–pathogen interactions. The information available so far comes from *in vivo* cross linking experiments and the effects of mutations of the Zalpha domains on the localization of the protein.

4.1. Nucleic acids bound by Zalpha *in vivo*

Pull-down experiments of genomic DNA segments probed for Zalpha binding reveal an enrichment in centromeric repeats [69] and probably reflect regions of Z-DNA formation rather than a functional association between the mostly cytoplasmic proteins and centromeres.

Similar experiments where Zalpha is cross-linked *in vivo* to cellular RNA identified specific regions of ribosomal RNA of both bacterial and eukaryotic ribosomes [70] associated with the domain. Zalpha mediated binding of ADAR1 to the ribosome is shown to inhibit translation and the authors propose that the translation of ADAR1-bound mRNAs may be specifically inhibited this way. Such an interference with the translation machinery would be in agreement with the finding that the Zalpha domain of DAI is responsible for an association of DAI with stress granules that contain stalled translation preinitiation complexes [71]. How such action could be reconciled with a proviral role of ADAR1 and the general upregulation of translation through the modulation of PKR activity remains to be seen.

The accumulation of negative supercoiling introduced by RNA polymerases during transcription plays a key role in the stabilization of Z-DNA *in vivo* [72]. In recent years it has been shown that detection of certain types of dsDNA in the cytoplasm proceeds through its transcription by RNA polymerase III and subsequent recognition of the resulting 5'-triphosphate-RNA by the RIG-I helicase [73]. It is conceivable that Pol III transcription can be the source of negative supercoiling that gives rise to Z-DNA formation and the site of attachment for Zalpha-containing proteins. Although E3L is shown to inhibit RIG-I mediated activation of interferons against poly-AT DNA, this activity appears to be independent from its N-terminal Zalpha domain [74]. The study of other types of DNA activator sequences maybe necessary to reveal an involvement of Zalpha domains on the Pol III pathway.

5. Concluding remarks

The universal chemical and structural nature of nucleic acids presents a great challenge for cells that have to distinguish between self and non-self. CpG sequences and their unique structural features appear to have a central role in this distinction both for Toll mediated recognition and for cytoplasmic receptors where Zalpha domains may have a central role. Deregulation of this recognition and of the RNA editing process not only can affect the progress of pathogen-induced disease but may also have a crucial role in autoimmune diseases and cancer.

Acknowledgements

I thank Dr. Vasco Barreto, Krzysztof Kus and Dr. Matteo de Rosa for valuable comments on the manuscript. The author would like to acknowledge funding support from the Marie Curie IRG program [PIRG03-GA-2008-23100] and the Portuguese Foundation for Research and Technology (FCT) [PTDC/BIA-PRO/112962/2009].

References

- [1] Bass BL, Weintraub H. An unwinding activity that covalently modifies its double-stranded RNA substrate. *Cell* 1988;55:1089–98.
- [2] O'Connell MA, R.N.A. editing: rewriting receptors. *Curr Biol* 1997;7:R437–9.
- [3] Laurencikienė J, Kallman AM, Fong N, Bentley DL, Ohman M. R.N.A. editing and alternative splicing: the importance of co-transcriptional coordination. *EMBO Rep* 2006;7:303–7.
- [4] O'Connell MA, Keegan LP. Drosha versus ADAR: wrangling over pri-miRNA. *Nat Struct Mol Biol* 2006;13:3–4.
- [5] Polson AG, Bass BL. Preferential selection of adenosines for modification by double-stranded RNA adenosine deaminase. *EMBO J* 1994;13:5701–11.
- [6] Eggington JM, Greene T, Bass BL. Predicting sites of ADAR editing in double-stranded RNA. *Nat Commun* 2011;2:319.
- [7] Schmauss C, Howe JR. R.N.A. editing of neurotransmitter receptors in the mammalian brain. *Sci STKE* 2002;2002:PE26.
- [8] Ohlson J, Pedersen JS, Haussler D, Ohman M. Editing modifies the GABA(A) receptor subunit alpha3. *RNA* 2007;13:698–703.
- [9] Semenov EP, Pak WL. Diversification of *Drosophila* chloride channel gene by multiple posttranscriptional mRNA modifications. *J Neurochem* 1999;72:66–72.
- [10] Grauso M, Reenan RA, Culetto E, Sattelle DB. Novel putative nicotinic acetylcholine receptor subunit genes, Dalpha5, Dalpha6 and Dalpha7, in *Drosophila melanogaster* identify a new and highly conserved target of adenosine deaminase acting on RNA-mediated A-to-I pre-mRNA editing. *Genetics* 2002;160:1519–33.
- [11] Hoopengardner B, Bhalla T, Staber C, Reenan R. Nervous system targets of RNA editing identified by comparative genomics. *Science* 2003;301:832–6.
- [12] Athanasiadis A, Rich A, Maas S. Widespread A-to-I RNA editing of Alu-containing mRNAs in the human transcriptome. *PLoS Biol* 2004;2:e391.
- [13] Blow M, Futreal PA, Wooster R, Stratton MR. A survey of RNA editing in human brain. *Genome Res* 2004;14:2379–87.
- [14] Kim DD, Kim TT, Walsh T, Kobayashi Y, Matise TC, Buyske S, et al. Widespread RNA editing of embedded alu elements in the human transcriptome. *Genome Res* 2004;14:1719–25.
- [15] Levanon EY, Eisenberg E, Yelin R, Nemzer S, Hallegger M, Shemesh R, et al. Systematic identification of abundant A-to-I editing sites in the human transcriptome. *Nat Biotechnol* 2004;22:1001–5.
- [16] Ding SW, Voinnet O. Antiviral immunity directed by small RNAs. *Cell* 2007;130:413–26.
- [17] Gantier MP, Williams BR. The response of mammalian cells to double-stranded RNA. *Cytokine Growth Factor Rev* 2007;18:363–71.
- [18] Cattaneo R, Schmid A, Eschle D, Baczkó K, ter Meulen V, Billeter MA. Biased hypermutation and other genetic changes in defective measles viruses in human brain infections. *Cell* 1988;55:255–65.
- [19] Cattaneo R. Biased (A → I) hypermutation of animal RNA virus genomes. *Curr Opin Genet Dev* 1994;4:895–900.
- [20] Bass BL. R.N.A. editing and hypermutation by adenosine deamination. *Trends Biochem Sci* 1997;22:157–62.
- [21] Samuel CE. Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral. *Virology* 2011;411:180–93.
- [22] Carpenter JA, Keegan LP, Wilfert L, O'Connell MA, Jiggins FM. Evidence for ADAR-induced hypermutation of the *Drosophila* sigma virus (Rhabdoviridae). *BMC Genet* 2009;10:75.
- [23] George CX, Samuel CE. Host response to polyomavirus infection is modulated by RNA adenosine deaminase ADAR1 but not by ADAR2. *J Virol* 2011;85:8338–47.
- [24] Casey JL, Gerin JL. Hepatitis D virus RNA editing: specific modification of adenosine in the antigenomic RNA. *J Virol* 1995;69:7593–600.
- [25] Sharmeen L, Bass B, Sonenberg N, Weintraub H, Groudine M. Tat-dependent adenosine-to-inosine modification of wild-type transactivation response RNA. *Proc Natl Acad Sci U S A* 1991;88:8096–100.
- [26] Doria M, Neri F, Gallo A, Farace MG, Michienzi A. Editing of HIV-1 RNA by the double-stranded RNA deaminase ADAR1 stimulates viral infection. *Nucleic Acids Res* 2009;37:5848–58.
- [27] Phuphuakrat A, Kraiwong R, Boonarkart C, Lauhakirti D, Lee TH, Auewarakul P. Double-stranded RNA adenosine deaminases enhance expression of human immunodeficiency virus type 1 proteins. *J Virol* 2008;82:10864–72.
- [28] Pfeffer S, Sewer A, Lagos-Quintana M, Sheridan R, Sander C, Grasser FA, et al. Identification of microRNAs of the herpesvirus family. *Nat Methods* 2005;2:269–76.
- [29] Gandy SZ, Linnstaedt SD, Muralidhar S, Cashman KA, Rosenthal LJ, Casey JL. R.N.A. editing of the human herpesvirus 8 kaposin transcript eliminates its transforming activity and is induced during lytic replication. *J Virol* 2007;81:13544–51.
- [30] George CX, Samuel CE. Human RNA-specific adenosine deaminase ADAR1 transcripts possess alternative exon 1 structures that initiate from different promoters, one constitutively active and the other interferon inducible. *Proc Natl Acad Sci U S A* 1999;96:4621–6.
- [31] Hartner JC, Schmittwolf C, Kispert A, Muller AM, Higuchi M, Seeburg PH. Liver disintegration in the mouse embryo caused by deficiency in the RNA-editing enzyme ADAR1. *J Biol Chem* 2004;279:4894–902.
- [32] Wang Q, Miyakoda M, Yang W, Khillan J, Stachura DL, Weiss MJ, et al. Stress-induced apoptosis associated with null mutation of ADAR1 RNA editing deaminase gene. *J Biol Chem* 2004;279:4952–61.

- [33] Hartner JC, Walkley CR, Lu J, Orkin SH. ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling. *Nat Immunol* 2009;10:109–15.
- [34] Ward SV, George CX, Welch MJ, Liou LY, Hahm B, Lewicki H, et al. RNA editing enzyme adenosine deaminase is a restriction factor for controlling measles virus replication that also is required for embryogenesis. *Proc Natl Acad Sci U S A* 2011;108:331–6.
- [35] Toth AM, Li Z, Cattaneo R, Samuel CE. RNA-specific adenosine deaminase ADAR1 suppresses measles virus-induced apoptosis and activation of protein kinase PKR. *J Biol Chem* 2009.
- [36] Gelinás JF, Clerzius G, Shaw E, Gatignol A. Enhancement of replication of RNA viruses by ADAR1 via RNA editing and inhibition of RNA-activated protein kinase. *J Virol* 2011;85:8460–6.
- [37] Wang Y, Samuel CE. Adenosine deaminase ADAR1 increases gene expression at the translational level by decreasing protein kinase PKR dependent eIF-2alpha phosphorylation. *J Mol Biol* 2009.
- [38] Li Z, Wolff KC, Samuel CE. RNA adenosine deaminase ADAR1 deficiency leads to increased activation of protein kinase PKR and reduced vesicular stomatitis virus growth following interferon treatment. *Virology* 2010;396:316–22.
- [39] Nejeplinska J, Malik R, Filkowski J, Flemr M, Filipowicz W, Svoboda P. dsRNA expression in the mouse elicits RNAi in oocytes and low adenosine deamination in somatic cells. *Nucleic Acids Res* 2011.
- [40] Tonkin LA, Bass BL. Mutations in RNAi rescue aberrant chemotaxis of ADAR mutants. *Science* 2003;302:1725.
- [41] Wu D, Lamm AT, Fire AZ. Competition between ADAR and RNAi pathways for an extensive class of RNA targets. *Nat Struct Mol Biol* 2011.
- [42] Yang W, Wang Q, Howell KL, Lee JT, Cho DS, Murray JM, et al. ADAR1 RNA deaminase limits short interfering RNA efficacy in mammalian cells. *J Biol Chem* 2005;280:3946–53.
- [43] Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. *Nature* 2011;472:481–5.
- [44] Herbert AG, Spitzner JR, Lowenhaupt K, Rich A. Z-DNA binding protein from chicken blood nuclei. *Proc Natl Acad Sci U S A* 1993;90:3339–42.
- [45] Herbert A, Alfken J, Kim YG, Mian IS, Nishikura K, Rich A. A Z-DNA binding domain present in the human editing enzyme, double-stranded RNA adenosine deaminase. *Proc Natl Acad Sci U S A* 1997;94:8421–6.
- [46] Wang AH, Quigley GJ, Kolpak FJ, Crawford JL, van Boom JH, van der Marel G, et al. Molecular structure of a left-handed double helical DNA fragment at atomic resolution. *Nature* 1979;282:680–6.
- [47] Schwartz T, Rould MA, Lowenhaupt K, Herbert A, Rich A. Crystal structure of the Zalpha domain of the human editing enzyme ADAR1 bound to left-handed Z-DNA. *Science* 1999;284:1841–5.
- [48] Schade M, Turner CJ, Lowenhaupt K, Rich A, Herbert A. Structure–function analysis of the Z-DNA-binding domain Zalpha of dsRNA adenosine deaminase type I reveals similarity to the (alpha + beta) family of helix–turn–helix proteins. *EMBO J* 1999;18:470–9.
- [49] Ha SC, Choi J, Hwang HY, Rich A, Kim YG, Kim KK. The structures of non-CG-repeat Z-DNAs co-crystallized with the Z-DNA-binding domain, hZalpha (ADAR1). *Nucleic Acids Res* 2009;37:629–37.
- [50] Ha SC, Lowenhaupt K, Rich A, Kim YG, Kim KK. Crystal structure of a junction between B-DNA and Z-DNA reveals two extruded bases. *Nature* 2005;437:1183–6.
- [51] de Rosa M, de Sanctis D, Rosario AL, Archer M, Rich A, Athanasiadis A, et al. Crystal structure of a junction between two Z-DNA helices. *Proc Natl Acad Sci U S A* 2010;107:9088–92.
- [52] Hall K, Cruz P, Tinoco Jr I, Jovin TM, van de Sande JH. ‘Z-RNA’—a left-handed RNA double helix. *Nature* 1984;311:584–6.
- [53] Brown 2nd BA, Lowenhaupt K, Wilbert CM, Hanlon EB, Rich A. The zalpha domain of the editing enzyme dsRNA adenosine deaminase binds left-handed Z-RNA as well as Z-DNA. *Proc Natl Acad Sci U S A* 2000;97:13532–6.
- [54] Placido D, Brown 2nd BA, Lowenhaupt K, Rich A, Athanasiadis A. A left-handed RNA double helix bound by the Z alpha domain of the RNA-editing enzyme ADAR1. *Structure* 2007;15:395–404.
- [55] Schwartz T, Behlke J, Lowenhaupt K, Heinemann U, Rich A. Structure of the DLM-1–Z-DNA complex reveals a conserved family of Z-DNA-binding proteins. *Nat Struct Biol* 2001;8:761–5.
- [56] Ha SC, Kim D, Hwang HY, Rich A, Kim YG, Kim KK. The crystal structure of the second Z-DNA binding domain of human DAI (ZBP1) in complex with Z-DNA reveals an unusual binding mode to Z-DNA. *Proc Natl Acad Sci U S A* 2008;105:20671–6.
- [57] Kim K, Khayrutdinov BI, Lee CK, Cheong HK, Kang SW, Park H, et al. Solution structure of the Z{beta} domain of human DNA-dependent activator of IFN-regulatory factors and its binding modes to B- and Z-DNAs. *Proc Natl Acad Sci U S A* 2011.
- [58] Ha SC, Lokanath NK, Van Quyen D, Wu CA, Lowenhaupt K, Rich A, et al. A poxvirus protein forms a complex with left-handed Z-DNA: crystal structure of a Yatopoxvirus Zalpha bound to DNA. *Proc Natl Acad Sci U S A* 2004;101:14367–72.
- [59] Rothenburg S, Deigendesch N, Dittmar K, Koch-Nolte F, Haag F, Lowenhaupt K, et al. A PKR-like eukaryotic initiation factor 2alpha kinase from zebrafish contains Z-DNA binding domains instead of dsRNA binding domains. *Proc Natl Acad Sci U S A* 2005;102:1602–7.
- [60] Takaoka A, Wang Z, Choi MK, Yanai H, Negishi H, Ban T, et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. *Nature* 2007;448:501–5.
- [61] Wang Z, Choi MK, Ban T, Yanai H, Negishi H, Lu Y, et al. Regulation of innate immune responses by DAI (DLM-1/ZBP1) and other DNA-sensing molecules. *Proc Natl Acad Sci U S A* 2008;105:5477–82.
- [62] DeFilippis VR, Alvarado D, Sali T, Rothenburg S, Fruh K. Human cytomegalovirus induces the interferon response via the DNA sensor ZBP1. *J Virol* 2010;84:585–98.
- [63] Furr SR, Chauhan VS, Moerdyk-Schauwecker MJ, Marriott I. A role for DNA-dependent activator of interferon regulatory factor in the recognition of herpes simplex virus type 1 by glial cells. *J Neuroinflammation* 2011;8:99.
- [64] Lippmann J, Rothenburg S, Deigendesch N, Eitel J, Meixenberger K, van Laak V, et al. IFNbeta responses induced by intracellular bacteria or cytosolic DNA in different human cells do not require ZBP1 (DLM-1/DAI). *Cell Microbiol* 2008;10:2579–88.
- [65] Bergan V, Jagus R, Lauksund S, Kileng O, Robertsen B. The Atlantic salmon Z-DNA binding protein kinase phosphorylates translation initiation factor 2 alpha and constitutes a unique orthologue to the mammalian dsRNA-activated protein kinase R. *FEBS J* 2008;275:184–97.
- [66] Kim YG, Muralinath M, Brandt T, Pearcy M, Hauns K, Lowenhaupt K, et al. A role for Z-DNA binding in vaccinia virus pathogenesis. *Proc Natl Acad Sci U S A* 2003;100:6974–9.
- [67] Langland JO, Kash JC, Carter V, Thomas MJ, Katze MG, Jacobs BL. Suppression of proinflammatory signal transduction and gene expression by the dual nucleic acid binding domains of the vaccinia virus E3L proteins. *J Virol* 2006;80:10083–95.
- [68] Athanasiadis A, Placido D, Maas S, Brown 2nd BA, Lowenhaupt K, Rich A. The crystal structure of the Zbeta domain of the RNA-editing enzyme ADAR1 reveals distinct conserved surfaces among Z-domains. *J Mol Biol* 2005;351:496–507.
- [69] Li H, Xiao J, Li J, Lu L, Feng S, Droge P. Human genomic Z-DNA segments probed by the Z alpha domain of ADAR1. *Nucleic Acids Res* 2009;37:2737–46.
- [70] Feng S, Li H, Zhao J, Pervushin K, Lowenhaupt K, Schwartz TU, et al. Alternate rRNA secondary structures as regulators of translation. *Nat Struct Mol Biol* 2011;18:169–76.
- [71] Deigendesch N, Koch-Nolte F, Rothenburg S. ZBP1 subcellular localization and association with stress granules is controlled by its Z-DNA binding domains. *Nucleic Acids Res* 2006;34:5007–20.
- [72] Nordheim A, Rich A. Negatively supercoiled simian virus 40 DNA contains Z-DNA segments within transcriptional enhancer sequences. *Nature* 1983;303:674–9.
- [73] Ablasser A, Bauernfeind F, Hartmann G, Latz E, Fitzgerald KA, Hornung V. RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. *Nat Immunol* 2009;10:1065–72.
- [74] Valentine R, Smith GL. Inhibition of the RNA polymerase III-mediated dsDNA sensing pathway of innate immunity by vaccinia virus protein E3. *J Gen Virol* 2010.